Abstract:Much effort has been made to uncover the cellular heterogeneities of human hearts by single-nucleus RNA sequencing. However, the cardiac transcriptional regulation networks have not been systematically described because of the limitations in detecting transcription factors. In this study, we optimized a pipeline for isolating nuclei and conducting single-nucleus RNA sequencing targeted to detect a higher number of cell signal genes and an optimal number of transcription factors. With this unbiased protocol, we characterized the cellular composition of healthy human hearts and investigated the transcriptional regulation networks involved in determining the cellular identities and functions of the main cardiac cell subtypes. Particularly in fibroblasts, a novel regulator, PKNOX2 , was identified as being associated with physiological fibroblast activation in healthy hearts. To validate the roles of these transcription factors in maintaining homeostasis, we used single-nucleus RNA-sequencing analysis of transplanted failing hearts focusing on fibroblast remodelling. The trajectory analysis suggested that PKNOX2 was abnormally decreased from fibroblast activation to pathological myofibroblast formation. Both gain- and loss-of-function in vitro experiments demonstrated the inhibitory role of PKNOX2 in pathological fibrosis remodelling. Moreover, fibroblast-specific overexpression and knockout of PKNOX2 in a heart failure mouse model induced by transverse aortic constriction surgery significantly improved and aggravated myocardial fibrosis, respectively. In summary, this study established a high-quality pipeline for single-nucleus RNA-sequencing analysis of heart muscle. With this optimized protocol, we described the transcriptional regulation networks of the main cardiac cell subtypes and identified PKNOX2 as a novel regulator in suppressing fibrosis and a potential therapeutic target for future translational studies.

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on cardiac fibrosis and its regulatory mechanisms. Specifically: 1. **Optimizing single - nucleus RNA sequencing technology**: The researchers developed an optimized single - nucleus RNA sequencing (snRNA - seq) process to increase the number of detected cell - signaling genes and transcription factors. The optimization of this technology is crucial for in - depth understanding of the heterogeneity of cardiac cells and transcriptional regulatory networks. 2. **Describing the cardiac cell composition and transcriptional regulatory network**: Using the optimized snRNA - seq technology, the researchers characterized in detail the cell composition of healthy human hearts and explored the identity and functional determinants of major cardiac cell subtypes, especially the transcriptional regulatory network in fibroblasts. 3. **Discovering a new fibrosis - inhibiting factor PKNOX2**: In fibroblasts, the researchers identified a new regulator - PKNOX2, which is related to the activation of fibroblasts in the physiological state. Further research shows that the expression of PKNOX2 is significantly reduced under pathological conditions (such as heart failure), and in vitro experiments show that it has the effect of inhibiting pathological fibrosis remodeling. 4. **Verifying the function of PKNOX2**: Through transgenic mouse models, the researchers confirmed the role of PKNOX2 in cardiac fibrosis. Over - expression of PKNOX2 can significantly reduce myocardial fibrosis and cardiac dysfunction, while knockout of PKNOX2 will exacerbate these pathological changes. In summary, this study not only optimized the technical process of single - nucleus RNA sequencing, but also revealed the potential therapeutic value of PKNOX2 as a new fibrosis - inhibiting factor, providing a new target for future cardiovascular disease treatment.

PBX/Knotted 1 homeobox-2 (PKNOX2) is a novel regulator of myocardial fibrosis